Would be interested in your views on this?
Macquarie 05-Sep-13
Macquarie has surveyed 381 endocrinologists globally about testosterone therapy. The findings showed a lack of affinity for Axiron and a lack of product differentiation. This raises concerns about further market share gains and price. Moreover, the doctors, on average, said that 31% of new patients gave up the therapy within six months of beginning treatment.
The broker has concerns about the broader market outlook given high patient lapse rates, low product differentiation and high relative attractiveness of potential new products. Earnings forecasts are adjusted downwards for FY14-16. The rating is downgraded to Underperform from Neutral. The price target is reduced to $3.00 from $3.50.
Downgrade to Underperform from Neutral
- Forums
- ASX - By Stock
- ACR
- anyone got the macbank research?
anyone got the macbank research?
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ACR (ASX) to my watchlist
|
|||||
Last
6.2¢ |
Change
-0.002(3.13%) |
Mkt cap ! $18.02M |
Open | High | Low | Value | Volume |
6.4¢ | 6.4¢ | 6.2¢ | $19.56K | 306.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 165056 | 6.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.4¢ | 63158 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 165056 | 0.062 |
2 | 39093 | 0.060 |
1 | 20000 | 0.059 |
3 | 60723 | 0.058 |
1 | 10000 | 0.055 |
Price($) | Vol. | No. |
---|---|---|
0.064 | 63158 | 1 |
0.066 | 38550 | 1 |
0.067 | 46144 | 4 |
0.068 | 50000 | 1 |
0.069 | 30387 | 2 |
Last trade - 16.10pm 20/08/2024 (20 minute delay) ? |
Featured News
ACR (ASX) Chart |
The Watchlist
CC9
CHARIOT CORPORATION LTD
MD - Shanthar Pathmanathan, Geologist - David Trabert
MD - Shanthar Pathmanathan
Geologist - David Trabert
SPONSORED BY The Market Online